Found 29 clinical trials
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.
- 208 views
- 08 Nov, 2020
- 1 location
RA-PRO PRAGMATIC TRIAL (RA-PROPR)
medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in
- 0 views
- 04 Apr, 2023
- 19 locations
Abatacept Conversion in Kidney Transplantation
infusions to abatacept subcutaneous injections without a decrease in kidney function.The primary objective will be the difference in estimated GFR (eGFR) for abatacept and belatacept groups using a monthly
- 0 views
- 18 Sep, 2023
- 1 location
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis (ULTRA)
, abatacept and tocilizumab have been shown to be effective during GCA. However, the therapeutic effect of the first two is modest. As for tocilizumab, its use has many limitations: suspensive effect, many
- 0 views
- 27 Oct, 2022
- 1 location
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis (CRI-RA)
(RCTs) have explored the efficacy and safety of combining tumour necrosis factor (TNF) inhibitor with another biologic (anakinra, abatacept, rituximab or bimekizumab). Baricitinib is a selective
- 0 views
- 15 Mar, 2022
- 6 locations
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.
- 0 views
- 15 Jul, 2022
- 1 location
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery
- 0 views
- 04 Sep, 2023
- 1 location
Abatacept in Immune Checkpoint Inhibitor Myocarditis (ATRIUM)
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis
- 0 views
- 13 Sep, 2023
- 29 locations
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS (ACHLYS)
-series of over 100 patients. This study is a dose-finding Phase II trial where 3 abatacept IV regimen (A-10 mg/kg; B-20 mg/kg and C-25 mg/kg every week) will be tested aiming at reaching promptly
- 0 views
- 20 Oct, 2022
- 1 location
Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Abatacept in Combination With a Janus Kinase (JAK) Inhibitor
The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients
- 0 views
- 12 Oct, 2022
- 1 location